A study to test different doses of obrixtamig (BI 764532) combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502728-30-00

Acronym

1438-0002

Enrollment

Registered

2023-06-12

Start date

2023-08-25

Completion date

Unknown

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large cells neuroendocrine lung carcinoma (LCNEC) expressing DLL3, Neuroendocrine carcinoma (NEC) or small cell carcinoma of any other origin expressing DLL3, Small Cell Lung Carcinoma expressing DLL3

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, France, Germany

Outcome results